☆ 4.7 Review

Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety

VACCINES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Rheumatology

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Michael Bonelli et al.

Summary: This study found that an additional booster vaccination is effective and safe for non-seroconverted patients after receiving conventional COVID-19 vaccination. Both vector and mRNA vaccines have comparable efficacy in enhancing humoral and cellular immune response, which is particularly important for immunosuppressed patients.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Letter Rheumatology

Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis

Claudius Speer et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

Davide Firinu et al.

Summary: The study found that patients with IMIDs have significantly reduced humoral immune response after receiving the BNT162b2 vaccine, especially those treated with anti-CD20 drugs. At T2, IMID patients had lower IgG levels compared to the HCW group, but there was no significant difference at T3. Age and the disease itself were correlated with immune response after vaccination, while treatment did not have a significant impact except for anti-CD20 drugs.

CLINICAL AND EXPERIMENTAL MEDICINE (2022)

添加到收藏夹

Article Immunology

Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters

Daniel Magliulo et al.

Summary: Rituximab treatment reduces immune response to SARS-CoV-2 vaccination, which is associated with hypogammaglobulinemia.

CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study

Natacha Madelon et al.

Summary: Despite impaired humoral responses, patients on anti-CD20 treatment who are at risk for severe COVID-19 can mount potent T-cell responses to mRNA COVID-19 vaccines. This could play an important role in the reduction of complications of COVID-19.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients A Randomized Clinical Trial

Roman Reindl-Schwaighofer et al.

Summary: Less than 50% of kidney transplant recipients developed antibodies against the SARS-CoV-2 spike protein after 2 doses of an mRNA vaccine. A third dose of either mRNA or vector vaccine increased antibody response in 39% of KTRs without prior immune response, but neutralizing antibodies and T-cell response remained low. Triple immunosuppression, longer time after transplant, and torque teno virus plasma levels were associated with vaccine response. Local pain was higher with mRNA vaccine, but systemic symptoms were similar between groups.

JAMA INTERNAL MEDICINE (2022)

添加到收藏夹

Article Rheumatology

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases

Cristiana Sieiro Santos et al.

Summary: Patients with IMRD receiving immunosuppressive therapies exhibit impaired immunogenicity after receiving mRNA SARS-CoV-2 vaccines, with drugs like methotrexate and azathioprine showing varying levels of impact on vaccine responses. Abatacept and B-cell depleting therapies have deleterious effects, while anticytokines help preserve immunogenicity. The effects of cumulative methotrexate and glucocorticoid doses on vaccine immunogenicity warrant consideration, and humoral and cellular responses show weak correlation while CD4 and CD8 responses are tightly correlated, suggesting a more nuanced evaluation than seroconversion alone.

RMD OPEN (2022)

添加到收藏夹

Editorial Material Rheumatology

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

Renaud Felten et al.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum et al.

Summary: This study investigates the humoral and cellular immune responses in rheumatoid arthritis patients treated with rituximab after receiving two or three doses of SARS-CoV-2 vaccines. The study finds that some patients do not have serological responses to two doses of the vaccine, but a third dose can enhance the cellular immune response. This is important for understanding the vaccine efficacy in immunocompromised patients.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Editorial Material Rheumatology

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

Kristin Schmiedeberg et al.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Letter Rheumatology

Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series

Caoilfhionn M. Connolly et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Clinical Neurology

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

S. Guerrieri et al.

Summary: This study found variable antibody production in multiple sclerosis patients receiving fingolimod or ocrelizumab treatments after receiving a complete SARS-CoV-2 vaccination course. Clinical features did not show a clear correlation with serological response. There is currently insufficient data to recommend against COVID-19 vaccination in these patients.

JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

Sapir Dreyer-Alster et al.

Summary: This study evaluated the safety and immune response of a third dose of COVID-19 BNT162b2 vaccine in patients with multiple sclerosis (MS). The results showed that the third dose of the vaccine was safe for MS patients and did not increase the risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments showed a significant increase in immune response following the third dose of vaccination.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Review Medicine, General & Internal

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

Ainsley Ryan Yan Bin Lee et al.

Summary: This systematic review and meta-analysis compared the efficacy of covid-19 vaccines between immunocompromised and immunocompetent individuals. The results showed that immunocompromised patients, especially organ transplant recipients, had significantly lower rates of seroconversion after covid-19 vaccination. A second dose of the vaccine consistently improved seroconversion in all patient groups, although the improvement was smaller for organ transplant recipients. Targeted interventions, including a third dose (booster) of the vaccine, should be performed for immunocompromised patients.

BMJ-BRITISH MEDICAL JOURNAL (2022)

添加到收藏夹

Article Clinical Neurology

Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab

Natacha Madelon et al.

Summary: This study aimed to investigate T-cell responses to the Omicron spike protein in patients with multiple sclerosis (MS) treated with anti-CD20 therapy before and after a third mRNA COVID-19 vaccination. The results showed that the third dose enhanced T-cell responses to all variants, suggesting that COVID-19 vaccination may protect patients taking B-cell-depleting drugs against severe complications from infection.

JAMA NEUROLOGY (2022)

添加到收藏夹

Letter Medicine, General & Internal

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?

Anat Achiron et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

添加到收藏夹

Editorial Material Rheumatology

Rheumatic disease and COVID-19: epidemiology and outcomes

Kimme L. Hyrich et al.

NATURE REVIEWS RHEUMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

添加到收藏夹

Review Rheumatology

COVID-19 vaccination and antirheumatic therapy

Jack Arnold et al.

Summary: This article discusses the impact of immunosuppressive therapy on COVID-19 vaccination, proposing a suggestion to temporarily suspend treatment to improve vaccine effectiveness, and urging decisions on withholding immunosuppressive therapy to be made in advance without sufficient data support.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Immunology

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis

Lutz Achtnichts et al.

Summary: Research indicates that individuals with MS who undergo CD20 depletion therapy have limited humoral immune response even after receiving a third dose of mRNA vaccine. Further investigation is needed to determine if T-cell responses can provide sufficient protection against CoV-2 infections in these individuals.

VACCINES (2021)

添加到收藏夹

Article Rheumatology

Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies

Ulf M. Geisen et al.

Summary: This study investigated the decline of humoral immune responses in CID patients after 6 months of COVID-19 vaccination. Patients receiving anti-TNF treatment showed significant declines in IgG and neutralizing antibodies levels. Early booster vaccinations should be considered for these patients due to the more pronounced declines in humoral responses.

RMD OPEN (2021)

添加到收藏夹

Article Rheumatology

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

Theerada Assawasaksakul et al.

Summary: Research suggests that a third dose of mRNA or viral vector vaccine following the initial CoronaVac inactivated vaccine series can elicit a strong immune response in patients with SLE, while being well tolerated.

RMD OPEN (2021)

添加到收藏夹

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Review Rheumatology

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

Marcia A. Friedman et al.

Summary: Patients with rheumatic diseases are at increased risk of infectious complications, and disease-modifying antirheumatic drugs can reduce the immunogenicity of common vaccines. Different medications have varying impacts on vaccine immunogenicity, with rituximab having the most substantial effect and Janus kinase and tumour necrosis factor inhibitors decreasing antibody titres. Emerging data suggest that the effect of these medications on the SARS-CoV-2 vaccine immunogenicity is similar to other vaccines, but more research is needed.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City

Medha Barbhaiya et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Immunology

Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients

Hannah Kelly et al.

Summary: COVID-19 vaccination is recommended for multiple sclerosis patients, although different types of vaccines may have varying impacts on their efficacy. It is important to carefully select vaccines for these patients, as some treatments may affect vaccine responses. Avoiding vaccines that could impact vaccine efficacy is crucial in treated patients.

JOURNAL OF NEUROIMMUNOLOGY (2021)

添加到收藏夹

Letter Urology & Nephrology

Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis

Sam Kant et al.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Clinical Neurology

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Livnat Brill et al.

Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.

JAMA NEUROLOGY (2021)

添加到收藏夹

Review Hematology

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

Abi Vijenthira et al.

Summary: The study found that patients receiving anti-CD20 therapy have poor responses to all types of vaccines, especially during treatment and at least 6 months post-treatment, with significantly lower SC rates compared to healthy and disease control groups. As time progresses, response to vaccination gradually improves, but even 12 months post-therapy, it may not reach the level of healthy controls.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Rheumatology

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry

Claudia Diniz Lopes Marques et al.

Summary: The study found that age over 50, the use of glucocorticoids and cyclophosphamide for immunosuppression were associated with unfavorable outcomes of COVID-19. Treatment with tumor necrosis factor inhibitor may have been protective, perhaps leading to the occurrence of the COVID-19 inflammatory process.

RMD OPEN (2021)

添加到收藏夹

Review Rheumatology

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Victoria Furer et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Review Rheumatology

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Alexandre Sepriano et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Health Care Sciences & Services

Methodological quality of case series studies: an introduction to the JBI critical appraisal tool

Zachary Munn et al.

JBI EVIDENCE SYNTHESIS (2020)

添加到收藏夹

Review Immunology

The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis

Marlene van Aalst et al.

VACCINE (2018)

添加到收藏夹

Article Rheumatology

Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine

J. Nagel et al.

LUPUS (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics

Ping Li et al.

FRONTIERS IN PHARMACOLOGY (2017)

添加到收藏夹

Review Health Care Sciences & Services

The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence

Zachary Munn et al.

INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT (2014)

添加到收藏夹

Article Immunology

Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

Robert A. Eisenberg et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2013)

添加到收藏夹

Review Rheumatology

The Effect of Infliximab and Timing of Vaccination on the Humoral Response to Influenza Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

Ori Elkayam et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Review Medicine, General & Internal

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

Annabel Kuek et al.

POSTGRADUATE MEDICAL JOURNAL (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.